BOSTON, Mass.—GE (NYSE:GE) announced today the completion of the sale of its BioPharma business to Danaher Corporation (NYSE:DHR) (“Danaher”) for approximately $20 billion of net proceeds. GE Chairman and CEO H. Lawrence Culp, Jr., said, “Completing the sale of BioPharma represents a critical milestone on our multi-year transformation, fortifying our considerable sources to de-risk our […]
To view this release online and get more information about Danaher Corporation: IR Room visit: https://investors.danaher.com/2020-03-31-Danaher-Completes-Acquisition-Of-The-Biopharma-Business-Of-General-Electric-Life-Sciences-Business-Will-Be-Called-Cytiva WASHINGTON — Danaher Corporation (NYSE: DHR) (“Danaher”) announced today the completion of its acquisition of the Biopharma business from General Electric Company’s (NYSE: GE) Life Sciences division. As part of Danaher, the business will be called Cytiva and will be a […]
Pay Invoice
Latest Blogs
-
SDi Predicts a Recovery Amid Headwinds
July 24, 2026 2:51 pm
-
EU Roadmap Provides Further Impetus for New Approach Methodologies
June 29, 2026 12:56 pm
-
MOBILion Expands into Proteomics MS Market
April 30, 2026 5:05 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.

